


Claims:

- 5 1. A compound of formula (I):



or a salt, solvate, or physiologically functional derivative thereof, wherein:

10

R¹ is selected from hydrogen, C₁-₆alkyl, hydroxy, cyano, nitro, halo, C₁-₆haloalkyl, XCO₂R⁸, -XC(O)NR⁷R⁸, -XNR⁸C(O)R⁷, -XNR⁸C(O)NR⁷R⁸, -XNR⁸C(O)NC(O)NR⁷R⁸, -XNR⁸SO₂R⁷, -XSO₂NR⁹R¹⁰, XSR⁸, XSOR⁸, XSO₂R⁸, -XNR⁷R⁸, -XNR⁸C(O)OR⁷,

15

or R¹ is selected from -X-aryl, -X-hetaryl, or -X-(aryloxy), each optionally substituted by 1 or 2 groups independently selected from hydroxy, C₁-₆alkoxy, halo, C₁-₆alkyl, C₁-₆haloalkyl, -NR⁸C(O)R⁷, SR⁸, SOR⁸, -SO₂R⁸, -SO₂NR⁹R¹⁰, -CO₂R⁸, -NR⁷R⁸, or hetaryl optionally substituted by 1 or 2 groups independently selected from hydroxy, C₁-₆alkoxy, halo, C₁-₆alkyl, or C₁-₆haloalkyl;

20

X is -(CH₂)ₑ- or C₂-₆ alkenylene;

q is an integer from 0 to 6, preferably 0 to 4;

25

R⁸ and R⁷ are independently selected from hydrogen, C₁-₆alkyl, C₃-₇cycloalkyl, aryl, hetaryl, hetaryl(C₁-₆alkyl)- and aryl(C₁-₆alkyl)- and R⁸ and R⁷ are each independently optionally substituted by 1 or 2 groups independently selected from halo, C₁-₆alkyl, C₃-₇ cycloalkyl, C₁-₆ alkoxy, C₁-₆haloalkyl, -NHC(O)(C₁-₆alkyl), -SO₂(C₁-₆alkyl), -SO₂(aryl), -CO₂H, and -CO₂(C₁-₄alkyl), -NH₂, -NH(C₁-₆alkyl), aryl(C₁-₆alkyl)-, aryl(C₂-₆alkenyl)-,

aryl(C₂₋₆alkynyl)-, hetaryl(C₁₋₆alkyl)-, -NHSO₂aryl, -NH(hetarylC₁₋₆alkyl), -NHSO₂hetaryl, -NHSO₂(C₁₋₆alkyl), -NHC(O)aryl, or -NHC(O)hetaryl:

R⁸ is selected from hydrogen, C₁₋₆alkyl and C₃₋₇ cycloalkyl;

5

or R⁷ and R⁸, together with the nitrogen atom to which they are bonded, form a 5-, 6- or 7-membered nitrogen – containing ring;

R⁹ and R¹⁰ are independently selected from hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, aryl, hetaryl, hetaryl(C₁₋₆alkyl)- and aryl(C₁₋₆alkyl)-, or R⁹ and R¹⁰, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7- membered nitrogen containing ring;

10

and R⁹ and R¹⁰ are each optionally substituted by one or two groups independently selected from halo, C₁₋₆alkyl, and C₃₋₇cycloalkyl, C₁₋₆haloalkyl;

15

R² is selected from hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, halo, aryl, aryl(C₁₋₆alkyl)-, C₁₋₆haloalkoxy, and C₁₋₆haloalkyl;

R³ is selected from hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, halo, aryl, aryl(C₁₋₆alkyl)-, C₁₋₆haloalkoxy, and C₁₋₆haloalkyl; and


20

R⁴ and R⁵ are independently selected from hydrogen and C₁₋₄ alkyl with the proviso that the total number of carbon atoms in R⁴ and R⁵ is not more than 4;


R^a and R^b each independently represent hydrogen or C₁₋₄alkyl;

25


Ar¹ is a group selected from



(a)




(b)



(c)

and



(d)

wherein R^{11} represents hydrogen, halogen, $-(CH_2)_rOR^{15}$, $-NR^{15}C(O)R^{16}$, $-NR^{15}SO_2R^{16}$, $-SO_2NR^{15}R^{16}$, $-NR^{15}R^{16}$, $-OC(O)R^{17}$ or $OC(O)NR^{15}R^{16}$,
and R^{12} represents hydrogen, halogen or C_{1-4} alkyl;

5

or R^{11} represents $-NHR^{18}$ and R^{12} and $-NHR^{18}$ together form a 5- or 6- membered heterocyclic ring;

R^{13} represents hydrogen, halogen, $-OR^{15}$ or $-NR^{15}R^{16}$;

10

R^{14} represents hydrogen, halogen, halo C_{1-4} alkyl, $-OR^{15}$, $-NR^{15}R^{16}$, $-OC(O)R^{17}$ or $OC(O)NR^{15}R^{16}$;

R^{15} and R^{16} each independently represents hydrogen or C_{1-4} alkyl, or in the groups

15

$-NR^{15}R^{16}$, $-SO_2NR^{15}R^{16}$ and $-OC(O)NR^{15}R^{16}$, R^{15} and R^{16} independently represent hydrogen or C_{1-4} alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

R^{17} represents an aryl group which may be unsubstituted or substituted by one or more substituents selected from halogen, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy or halo C_{1-4} alkyl; and

5 r is zero or an integer from 1 to 4;

Z is O, CH_2 - or a single bond;

n is an integer of from 1 to 4;

10 m is zero or an integer of from 1 to 4;


p is zero or an integer of from 1 to 3;

k is an integer from 1 to 3; and

t is zero or 1.

15

2. A compound of formula (Ia):



or a salt, solvate, or physiologically functional derivative thereof, wherein:

20

k is an integer from 1 to 3;

n is an integer of from 1 to 4;

m is an integer of from 2 to 4;

p is an integer of from 1 to 4;

25 Z is O or CH_2 ;

R^1 is selected from hydrogen, C_{1-6} alkyl, hydroxy, cyano, nitro, halo, C_{1-6} haloalkyl, XCO_2R^8 , $-XC(O)NR^7R^8$, $-XNR^6C(O)R^7$, $-XNR^6C(O)NR^7R^8$, $-XNR^6C(O)NC(O)NR^7R^8$, $-XNR^6SO_2R^7$, $-XSO_2NR^9R^{10}$, XSR^6 , $XSOR^6$, XSO_2R^6 ,

30 $-XNR^7R^8$, $-XNR^6C(O)OR^7$,

or R¹ is selected from -X-aryl, -X-hetaryl, or -X-(aryloxy), each optionally substituted by 1 or 2 groups independently selected from hydroxy, C₁₋₆alkoxy, halo, C₁₋₆alkyl, C₁₋₆haloalkyl, -NR⁶C(O)R⁷, SR⁶, SOR⁶, -SO₂R⁶, -SO₂NR⁹R¹⁰, -CO₂R⁸, -NR⁷R⁸, or hetaryl optionally substituted by 1 or 2 groups independently selected from hydroxy, C₁₋₆alkoxy, halo, C₁₋₆alkyl, or C₁₋₆haloalkyl;

X is -(CH₂)_q- or C₂₋₆ alkenylene;

q is an integer from 0 to 6;

R⁶ and R⁷ are independently selected from hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, aryl, hetaryl, hetaryl(C₁₋₆alkyl)- and aryl(C₁₋₆alkyl)- and R⁶ and R⁷ are each independently optionally substituted by 1 or 2 groups independently selected from halo, C₁₋₆alkyl, C₃₋₇ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆haloalkyl, -NHC(O)(C₁₋₆alkyl), -SO₂(C₁₋₆alkyl), -SO₂(aryl), -CO₂H, and -CO₂(C₁₋₄alkyl), -NH₂, -NH(C₁₋₆alkyl), aryl(C₁₋₆alkyl)-, aryl(C₂₋₆alkenyl)-, aryl(C₂₋₆alkynyl)-, hetaryl(C₁₋₆alkyl)-, -NHSO₂aryl, -NH(hetarylC₁₋₆alkyl), -NHSO₂hetaryl, -NHSO₂(C₁₋₆alkyl), -NHC(O)aryl, or -NHC(O)hetaryl;

R⁸ is selected from hydrogen, C₁₋₆alkyl and C₃₋₇ cycloalkyl;

or R⁷ and R⁸, together with the nitrogen atom to which they are bonded, form a 5-, 6- or 7-membered nitrogen – containing ring;

R⁹ and R¹⁰ are independently selected from hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, aryl, hetaryl, hetaryl(C₁₋₆alkyl)- and aryl(C₁₋₆alkyl)-, or R⁹ and R¹⁰, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7- membered nitrogen containing ring;


and R⁹ and R¹⁰ are each optionally substituted by one or two groups independently selected from halo, C₁₋₆alkyl, and C₃₋₇cycloalkyl, C₁₋₆haloalkyl;

R² is selected from hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, halo, aryl, aryl(C₁₋₆alkyl)-, C₁₋₆haloalkoxy, and C₁₋₆haloalkyl;


R³ is selected from hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, halo, aryl, aryl(C₁₋₆alkyl)-, C₁₋₆haloalkoxy, and C₁₋₆haloalkyl; and

R^4 and R^5 are independently selected from hydrogen and C_{1-4} alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;


Ar^1 is a group selected from



(a)




(b)



(c)

and



(d)

5

wherein R^{11} represents halogen, $-(CH_2)_iOR^{15}$, $-NR^{15}C(O)R^{16}$, $-NR^{15}SO_2R^{16}$, $-SO_2NR^{15}R^{16}$, $-NR^{15}R^{16}$, $-OC(O)R^{17}$ or $OC(O)NR^{15}R^{16}$, and R^{12} represents hydrogen, halogen or C_{1-4} alkyl;

10 or R^{11} represents $-NHR^{18}$ and R^{12} and $-NHR^{18}$ together form a 5- or 6- membered heterocyclic ring;

R^{13} represents hydrogen, halogen, $-OR^{15}$ or $-NR^{15}R^{16}$;

15 R^{14} represents hydrogen, halogen, halo C_{1-4} alkyl, $-OR^{15}$, $-NR^{15}R^{16}$, $-OC(O)R^{17}$ or $OC(O)NR^{15}R^{16}$

R^{15} and R^{16} each independently represents hydrogen or C_{1-4} alkyl, or in the groups

$-\text{NR}^{15}\text{R}^{16}$, $-\text{SO}_2\text{NR}^{15}\text{R}^{16}$ and $-\text{OC}(\text{O})\text{NR}^{15}\text{R}^{16}$, R^{15} and R^{16} independently represent hydrogen or C_{1-4} alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

- 5 R^{17} represents an aryl group which may be unsubstituted or substituted by one or more substituents selected from halogen, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy or halo C_{1-4} alkyl; and

r is zero or an integer from 1 to 4.

10

3. A compound according to claim 1 or claim 2 wherein the group R^1 is selected from hydrogen, C_{1-4} alkyl, hydroxy, halo, $-\text{NR}^6\text{C}(\text{O})\text{NR}^7\text{R}^8$, $-\text{NR}^6\text{C}(\text{O})\text{R}^7$, $-\text{SO}_2\text{NR}^9\text{R}^{10}$, $-\text{SOR}^6$, $-\text{SO}_2\text{R}^6$, and $-\text{NR}^6\text{SO}_2\text{R}^7$ wherein R^6 and R^7 are as defined in claim 1 or claim 2.


- 15 4. A compound according to any of claims 1 to 3 wherein R^2 and R^3 are independently selected from hydrogen, hydroxyl, halogen, halo C_{1-6} alkyl, C_{1-6} alkyl, C_{1-6} alkoxy and halo C_{1-6} alkoxy.

- 20 5. A compound according to any of claims 1 to 4 wherein R^4 and R^5 each represent hydrogen.

6. A compound according to any of claims 1 to 5 wherein R^a and R^b each represent hydrogen.

- 25 7. A compound according to any of claims 1 to 6 wherein the group Ar^1 is selected from groups (a) and (b) as defined in claim 1.

8. A compound according to claim 7 wherein the group (a) is a group of formula (i):



(i)

30

9. A compound according to claim 1 selected from:

35

- 4-((1*R*)-2-[[2-(3-[[2-(Benzyloxy)ethoxy]methyl]phenyl)ethyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
 4-((1*R*)-2-[[2-(3-[[2-(Benzyloxy)methyl]phenyl)ethyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
 5 2-(Hydroxymethyl)-4-((1*R*)-1-hydroxy-2-[[2-(3-[[3-phenylpropoxy]methyl]phenyl)ethyl]amino]ethyl)phenol;
 2-(Hydroxymethyl)-4-((1*R*)-1-hydroxy-2-[[2-(3-[[4-phenylbutoxy]methyl]phenyl)ethyl]amino]ethyl)phenol;
 4-((1*R*)-2-[[2-(3-[[3-(Benzyloxy)propoxy]methyl]phenyl)ethyl]amino]-1-hydroxyethyl)-2-
 10 (hydroxymethyl)phenol;
 4-((1*R*)-2-[[2-(4-[[2-(Benzyloxy)ethoxy]methyl]phenyl)ethyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
 2-(Hydroxymethyl)-4-((1*R*)-1-hydroxy-2-[[2-(3-[[2-phenylethoxy]methyl]phenyl)ethyl]amino]ethyl)phenol;
 15 4-((1*R*)-2-[[2-(3-[[2-(6-Dichlorobenzyl)oxy]methyl]phenyl)ethyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
 4-((1*R*)-1-Hydroxy-2-[[2-(3-[[2-(2-methoxyphenyl)ethoxy]methyl]phenyl)ethyl]amino)ethyl)-2-(hydroxymethyl)phenol;
 4-((1*R*)-1-Hydroxy-2-[[2-(3-[[2-(3-methoxyphenyl)ethoxy]methyl]phenyl)ethyl]amino)ethyl)-
 20 2-(hydroxymethyl)phenol;
 4-((1*R*)-1-Hydroxy-2-[[2-(3-[[2-(4-methoxyphenyl)ethoxy]methyl]phenyl)ethyl]amino)ethyl)-2-(hydroxymethyl)phenol;
 3-[4-({3-[2-((2*R*)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino]ethyl]benzyl)oxy]butyl]benzenesulfonamide;
 25 3-[[2-({3-[2-((2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino]ethyl]benzyl)oxy)ethoxy]methyl]benzonitrile;
 4-[(1*R*)-2-({2-[3-({2-[(2,6-dichlorobenzyl)oxy]ethoxy]methyl]phenyl)ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
 4-[(1*R*)-2-({2-[3-({2-[(3-fluorobenzyl)oxy]ethoxy]methyl]phenyl)ethyl]amino)-1-
 30 hydroxyethyl]-2-(hydroxymethyl)phenol;
 4-[(1*R*)-2-({2-[3-({2-[(3,5-dimethylbenzyl)oxy]ethoxy]methyl]phenyl)ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
 4-[(1*R*)-1-hydroxy-2-({2-[3-({2-[(3-methoxybenzyl)oxy]ethoxy]methyl]phenyl)ethyl]amino)ethyl]-2-(hydroxymethyl)phenol;
 35 2-(hydroxymethyl)-4-((1*R*)-1-hydroxy-2-[[2-(3-[[2-[(3-(trifluoromethoxy)benzyl)oxy]ethoxy]methyl]phenyl)ethyl]amino]ethyl)phenol;

- 4-((1R)-1-hydroxy-2-[[2-(3-[[4-(3-hydroxyphenyl)butoxy]methyl]phenyl)ethyl]amino]ethyl)-2-(hydroxymethyl)phenol;
- 4-[3-((3-[2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)ethyl]benzyl)oxy)propyl]benzonitrile;
- 5 4-[4-((3-[2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)ethyl]benzyl)oxy)butyl]benzonitrile;
- 3-[3-((3-[2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)ethyl]benzyl)oxy)propyl]benzonitrile;
- 2-(hydroxymethyl)-4-[(1R)-1-hydroxy-2-((2-[3-((3-[4-(methylsulfonyl)phenyl]propoxy)methyl)phenyl]ethyl]amino)ethyl]phenol;
- 10 2-(hydroxymethyl)-4-[(1R)-1-hydroxy-2-((2-[3-((4-(methylsulfonyl)benzyl)oxy)methyl)phenyl]ethyl]amino)ethyl]phenol;
- 4-((1R)-1-hydroxy-2-[[2-(3-[[2-(2-hydroxyphenyl)ethoxy]methyl]phenyl)ethyl]amino]ethyl)-2-(hydroxymethyl)phenol;
- 15 4-((1R)-1-hydroxy-2-[[2-(3-[[4-(4-hydroxybenzyl)oxy]methyl]phenyl)ethyl]amino]ethyl)-2-(hydroxymethyl)phenol;
- 4-((1R)-1-hydroxy-2-[[2-(3-[[3-(3-hydroxyphenyl)propoxy]methyl]phenyl)ethyl]amino]ethyl)-2-(hydroxymethyl)phenol;
- 4-[(1R)-2-((2-[3-((4-[4-(cyclopentylsulfonyl)phenyl]butoxy)methyl)phenyl]ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
- 20 4-[(1R)-2-((2-[3-((3-[4-(cyclopentylsulfonyl)phenyl]propoxy)methyl)phenyl]ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
- 4-[(1R)-2-((2-[3-((3-[3-(cyclopentylsulfonyl)phenyl]propoxy)methyl)phenyl]ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
- 25 4-[(1R)-1-hydroxy-2-((2-[3-((2-[3-(4-hydroxybenzyl)oxy]ethoxy)methyl)phenyl]ethyl]amino)ethyl]-2-(hydroxymethyl)phenol;
- 4-[(1R)-2-((2-[3-((2-[3-(cyclopentylsulfonyl)benzyl]oxy)ethoxy)methyl]phenyl]ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
- 4-[(1R)-2-((2-[3-((2-[3-(cyclopentylsulfinyl)benzyl]oxy)ethoxy)methyl]phenyl]ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
- 30 1-hydroxyethyl]-2-(hydroxymethyl)phenol;
- 4-[(1R)-2-((2-[3-((3-(cyclopentylsulfonyl)benzyl]oxy)methyl)phenyl]ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
- 4-[(1R)-2-((2-[3-((4-[3-(cyclopentylsulfinyl)phenyl]butoxy)methyl)phenyl]ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
- 35 3-[4-((3-[2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)ethyl]benzyl)oxy)butyl]benzonitrile;

- 2-(hydroxymethyl)-4-((1R)-1-hydroxy-2-((2-((3-((2-phenoxyethoxy)methyl)phenyl)ethyl)amino)ethyl)phenol;
 4-((1R)-2-((2-((3-((2-(3-fluorophenyl)ethoxy)methyl)phenyl)ethyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
 5 4-((1R)-2-((2-((3-((2-(4-fluorophenyl)ethoxy)methyl)phenyl)ethyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
 4-((1R)-2-((2-((3-((2-(2-fluorophenyl)ethoxy)methyl)phenyl)ethyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
 10 3-((3-((2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)ethyl)benzyl)oxy)methyl]benzonitrile;
 4-((3-((2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)ethyl)benzyl)oxy)methyl]benzonitrile;
 2-(hydroxymethyl)-4-((1R)-1-hydroxy-2-((2-((3-((1R)-1-phenylethyl)oxy)methyl)phenyl)ethyl)amino)ethyl]phenol;
 15 2-(hydroxymethyl)-4-((1R)-1-hydroxy-2-((2-((3-((1S)-1-phenylethyl)oxy)methyl)phenyl)ethyl)amino)ethyl]phenol;
 4-((1R)-2-((2-((3-((3,5-dimethylbenzyl)oxy)methyl)phenyl)ethyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
 4-((1R)-2-((2-((3-((2,6-dichlorobenzyl)oxy)methyl)phenyl)ethyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
 20 4-((1R)-2-((2-((3-((2-fluorobenzyl)oxy)methyl)phenyl)ethyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
 4-((1R)-2-((2-((3-((3-fluorobenzyl)oxy)methyl)phenyl)ethyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
 25 4-((1R)-2-((2-((3-((4-fluorobenzyl)oxy)methyl)phenyl)ethyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
 3-((4-((3-((2-((2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)ethyl)benzyl)oxy)butyl]benzamide;
 3-((2-((3-((2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)ethyl)benzyl)oxy)ethoxy)methyl]benzamide;
 30 3-((3-((2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)ethyl)benzyl)oxy)methyl]benzamide;
 4-((3-((2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)ethyl)benzyl)oxy)methyl]benzamide;
 35 3-((2-((3-((2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)ethyl)benzyl)oxy)ethyl]benzenesulfonamide;

3-[3-({3-[2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)propyl]benzenesulfonamide;
 4-((1*R*)-2-[[2-(3-[[4-(2,6-dichlorophenyl)butoxy]methyl]phenyl)ethyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
 5 *N*-{3-[4-({3-[2-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl}oxy)butyl]phenyl}urea;
 2-(hydroxymethyl)-4-((1*R*)-1-hydroxy-2-[[2-(3-[[2-(1-phenylethoxy)ethoxy]methyl]phenyl)ethyl]amino)ethyl)phenol;
 4-[(1*R*)-2-({2-[3-({2-[3-(cyclopentylsulfonyl)phenyl]ethoxy}methyl)phenyl]ethyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
 10 4-[(1*R*)-2-({2-[3-({4-[3-(cyclopentylsulfonyl)phenyl]butoxy}methyl)phenyl]ethyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;
 2-(hydroxymethyl)-4-[(1*R*)-1-hydroxy-2-({2-[3-({4-[3-(methylsulfonyl)phenyl]butoxy}methyl)phenyl]ethyl}amino)ethyl]phenol;
 15 4-((1*R*)-2-[[2-(3-[[3-(2,6-dichlorophenyl)propoxy]methyl]phenyl)ethyl]amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
 3-[[3-[2-({(2*R*)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)ethyl]benzyl]oxy)methyl]benzenesulfonamide.

or a salt, solvate or physiologically functional derivative thereof.

10. A method for the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which a selective β_2 -adrenoreceptor agonist is indicated, which comprises administration of a therapeutically effective amount of a compound of formula (I) according to any of claims 1 to 9, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

11. A compound of formula (I), according to any of claims 1 to 9, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for use in medical therapy.

12. A compound of formula (I), according to any of claims 1 to 9, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for use in the


prophylaxis or treatment of a clinical condition for which a selective β_2 -adrenoreceptor agonist is indicated.

5 13.. A pharmaceutical formulation comprising a compound of formula (I), according to any of claims 1 to 9, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

10 14. The use of a compound of formula (I), according to any of claims 1 to 9, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof in the manufacture of a medicament for the prophylaxis or treatment of a clinical condition for which a selective β_2 -adrenoreceptor agonist is indicated.

15 15. A process for the preparation of a compound of formula (I), according to any of claims 1 to 9, or a salt, solvate, or physiologically functional derivative thereof, which comprises:


(a) deprotection of a protected intermediate, for example of formula (II):




(II)

or a salt or solvate thereof, wherein R^1 , R^2 , R^3 , R^4 , R^5 , Z , k , m , n and p are as defined for the compound of formula (I), Ar^{1a} is Ar^1 or a protected form thereof and P^1 and P^2 each independently represents hydrogen or a protecting group provided that the compound of formula (II) contains at least one protecting group; or

(b) alkylation of an amine of formula (X)




wherein Ar^{1a} is as hereinbefore defined P^2 and P^1 are each independently either hydrogen or a protecting group, with a compound of formula (XI):




wherein R^1 , R^2 , R^3 , R^4 , R^5 , Z , k , m , n and p are as defined for the compound of formula (I) and L^1 is a leaving group;

(c) reacting a compound of formula (XII):




wherein Ar¹ and P¹ are as hereinbefore defined and L¹ is a leaving group, with an amine of formula (XIII):




or

d) reacting a compound of formula (X):



as hereinbefore defined,

with a compound of formula (XIV):



under conditions suitable to effect reductive amination;

followed by the following steps in any order:

(i) optional removal of any protecting groups;

(ii) optional separation of an enantiomer from a mixture of enantiomers;

(iii) optional conversion of the product to a corresponding salt, solvate,

or physiologically functional derivative thereof.